Pro 2013-021 (Jianfeng Group Corporate Bond Listing Announcement)-2
Release time:
2020-08-05
(四)发行人设立、上市及股本变更情况
1、发行人的设立
尖峰集团的前身是金华市水泥厂,经金华市人民政府“金政[1988]100号”文批准由金华市水泥厂为主体于1989年8月8日组建浙江尖峰水泥集团股份有限公司,1991年经金华市人民政府以“金政发[1991]38号”文批准浙江尖峰水泥集团股份有限公司与浙江省水泥制品厂联合,联合后的集团公司更名为浙江尖峰建材集团股份有限公司,国家经济体制改革委员会1993年以“体改生[1993]2号”文批准继续进行股份制试点,1993年经浙江省计划经济委员会、浙江省经济体制改革委员会以“浙江计经企[1993]269号”文批准更名为浙江尖峰集团股份有限公司并升格为省批企业集团。尖峰集团于1993年3月19日变更登记,取得金华市工商行政管理局14728065-X号企业法人营业执照,注册资本70,544,793元,其中国家股占总股本的61.10%,法人股占总股本的18.35%,个人股占总股本的20.55%,已经浙江会计师事务所浙会验[1993]第286号《验资报告》确认到位。
2、发行人发行上市
1993年,中国证监会以“证监发审字[1993]18号”文批准尖峰集团发行的个人股股票上市流通。上交所以“上证上字[93]第2050号”文批准本公司发行的1,450万个人股股票于1993年7月28日在上交所挂牌交易,股票简称“尖峰集团”,证券代码600668。发行人股票上市时总股本为70,544,793股,其中国家股43,097,993股,占总股本的61.10%;法人股12,946,800股,占总股本的18.35%;流通A股14,500,000股,占总股本的20.55%。
3、公募法人股
根据1993年6月浙江省经济体制改革委员会《关于同意调整法人股募集比价的函复》,1993年11月浙江省经济体制改革委员会以“浙经体改[1993]20号”文批准发行人将以1:2.3的溢价比例向社会募集法人股3,580万股,实际募集法人股15,116,100股。本次募集法人股结束后,发行人总股本增加至85,660,893股,其中,非流通股国家股43,097,993股,占总股本的50.31%;非流通股法人股28,062,900股,占总股本的32.76%;流通A股14,500,000股,占总股本的16.93%。1994年3月浙江省经济体制改革委员会以“浙经体改[1994]30号”文对此次增募进行了确认。募集资金已经浙江会计师事务所浙会验[1994]第103号《验资报告》确认到位。
4、1994年送、配股
经发行人1994年4月8日第二次股东大会决议通过,并经1994年4月浙江省经济体制改革委员会浙经体改[1994]58号文及浙江省国有资产管理局[1994]国资12号文批准,发行人以总股本85,660,893股为基数,向全体股东按10:2比例送股;根据金华市财政局《关于1993年度国有股送配方案的意见》、国家股股东和法人股股东放弃配股权的书面声明,发行人将向全体流通股股东以10配15比例配股。本次送、配股完成后,发行人的总股本增加至124,543,072股,其中非流通股国家股51,717,592股,占总股本41.53%,非流通股法人股33,675,480,占总股本的27.04%,流通A股为39,150,000股,占总股本的31.43%。募集资金已经浙江会计师事务所浙会验[1994]第168号《验资报告》确认到位。
5、1995年送股
经发行人1995年4月23日1994年度股东大会决议通过,发行人以总股本124,543,072股为基数,向全体股东以10:2比例送股。本次送股后,发行人的总股本增加至149,451,686股,其中非流通国家股62,061,110股,非流通法人股40,410,576股,流通A股为46,980,000股。
6、1996年配股
经发行人1996年3月16日1995年度股东大会决议通过,并经浙江省人民政府证券委员会“浙证委[1996]5号”及中国证监会“证监发审字[1996]11号”文批准,发行人以总股本149,451,686股为基数实施每10股配2.5股。根据国家国有资产管理局国资企函发[1995]225号文及浙江省国有资产管理局[1995]77号文,国家股股东同意有偿出让国家股应配股份未认购部分15,195,265股;法人股股东同意有偿出让全部10,102,650股的配股权,社会公众股股东可按10:5.4的比例受让国家股和法人股的部分配售权。本次配股后总股本增加至186,809,330股,其中非流通国家股62,381,110股,非流通法人股40,410,576股,非流通转配股25,292,644股,流通A股为58,725,000股。募集资金已经浙江会计师事务所浙会验字[1996]第137号《验资报告》确认到位。
7、1997年送股、公积金转增股本
经发行人1997年6月6日1996年度股东大会决议通过,发行人以总股本186,809,330股为基数,向全体股东每10股送2股,同时用资本公积金每10股转增3股,送股和转增后总股本增加至280,213,995股,其中非流通国家股93,571,665股,非流通法人股60,615,864股,转配股37,938,966股;流通A股为88,087,500股。
8、1998年配股
经发行人1997年6月6日1996年度股东大会决议通过,并经浙江省证券管理委员会浙证委[1997]151号文及中国证监会“证监上字[1998]21号”文批准,发行人以总股本280,213,995股为基数,按每10股配售2股的比例实施配股。根据国家国有资产管理局国资企函发[1997]107号文和浙江省国有资产管理局[1997]28号文批复同意,国家股股东同意有偿转让国家股应配股份未认购部分11,408,933股;法人股股东同意有偿转让法人股应配股份未认购部分12,096,994股,转配股股东和社会公众股股东除可按10:2比例认购本次配售股份外,还可按10:1.865
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31